Cargando…
Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
HER2, a well established oncogenic member of EGFR family, is among the most intensely investigated kinase drug targets. In contrast to hotspot mutations of EGFR, few mutations of HER2 locate in activation loop within kinase domain. We previously reported the molecular mechanism underlying hyper kina...
Autores principales: | Hu, Zexi, Hu, Yong, Liu, Xicheng, Xi, Rongwen, Zhang, Aiqun, Liu, Deruo, Xie, Qiang, Chen, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741629/ https://www.ncbi.nlm.nih.gov/pubmed/26375550 |
Ejemplares similares
-
Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2018) -
Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity
por: Hu, Zexi, et al.
Publicado: (2015) -
Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021) -
HER kinase inhibition in patients with HER2- and HER3-mutant
cancers
por: Hyman, David M., et al.
Publicado: (2018) -
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)